Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup
Dow Jones06:32
Health-care companies fell after weak earnings.
Pfizer declined as weakened COVID-19 drug demand weighed on quarterly sales.
Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 levels around 309.06 billion Danish kroner, or about $48.79 billion.
Merck shares rose after the Big Pharma company cited strong demand for oncology, respiratory, and cardiometabolic drugs for its brisk quarterly sales growth.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
February 03, 2026 17:32 ET (22:32 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments